Table 1.
Characteristics of the Patients at Baseline.*
| Characteristic | 81-mg Group (N = 7540) |
325-mg Group (N = 7536) |
|---|---|---|
| Median age (IQR) — yr | 67.7 (60.7–73.6) | 67.5 (60.7–73.5) |
| Female sex — no. (%) | 2307 (30.6) | 2417 (32.1) |
| Median weight (IQR) — kg | 90.0 (78.6–103.6) | 90.0 (78.2–104.1) |
| Race — no. (%) | ||
| White | 6014 (79.8) | 5976 (79.3) |
| Black | 664 (8.8) | 647 (8.6) |
| Hispanic ethnic group — no. (%) | 249 (3.3) | 232 (3.1) |
| Medical history — no. (%)† | ||
| Previous myocardial infarction | 2674 (35.6) | 2631 (35.0) |
| Previous coronary revascularization | 4034 (53.6) | 3943 (52.4) |
| Previous percutaneous coronary intervention | 3005 (40.0) | 2941 (39.1) |
| Previous coronary-artery bypass grafting | 1786 (23.8) | 1741 (23.2) |
| Hypertension | 6264 (83.3) | 6248 (83.1) |
| Dyslipidemia | 6472 (86.1) | 6474 (86.1) |
| Diabetes mellitus | 2820 (37.5) | 2856 (38.0) |
| Atrial fibrillation | 605 (8.0) | 628 (8.4) |
| Congestive heart failure | 1718 (22.8) | 1786 (23.8) |
| Chronic kidney disease | 1315 (17.5) | 1333 (17.7) |
| Peripheral artery disease | 1706 (22.7) | 1787(23.8) |
| Previous clinically significant gastrointestinal bleeding | 455 (6.1) | 495 (6.6) |
| Previous intracranial hemorrhage | 98 (1.3) | 110(1.5) |
| Current smoker — no. (%) | 696 (9.2) | 686 (9.1) |
| Aspirin use before trial | ||
| Missing data — no. (%) | 404 (5.4) | 569 (7.6) |
| No — no. (%) | 286 (3.8) | 280 (3.7) |
| Yes — no. (%) | 6850 (90.8) | 6687 (88.7) |
| 81 mg — no./total no. (%) | 5823/6850 (85.0) | 5724/6687 (85.6) |
| 162 mg — no./total no. (%) | 168/6850 (2.5) | 142/6687 (2.1) |
| 325 mg — no./total no. (%) | 845/6850 (12.3) | 812/6687 (12.1) |
| Other dose — no./total no. (%) | 14/6850 (0.2) | 9/6687 (0.1) |
*
Age, sex, race, ethnic group, tobacco use, and medication use before randomization were reported by the patients. A total of 980 patients chose “Prefer not to say” for race, and 1042 patients chose “Prefer not to say” for ethnic group. Percentages may not total 100 because of rounding. IQR denotes interquartile range.
†
A total of 7520 of 7540 patients (99.7%) in the 81-mg group and 7519 of 7536 patients (99.8%) in the 325-mg group had available medical history through electronic health record data. Percentages for medical history are based on the number of patients in each group with available medical history.